Molecular Modelling Studies and Angiotensin Converting Enzyme Inhibitory Activity of Some 4-Benzylidene-2-substitutedbenzoyl-6-phenyl-4,5-dihydropyridazin-3(2H)-ones

摘要

In continuation of our work related to the identification of pyridazinone derivatives as Angiotensin Converting Enzyme (ACE) inhibitors, we report herein the molecular modelling studies and ACE inhibitory activity of some 4-benzylidene-2-substitutedbenzoyl-6-phenyl-4,5-dihydropyridazin-3(2H)-one s(3a-3l). These compounds were prepared by the reaction of 2-(2-substitutedbenzoyl)-6-phenyl-4,5-dihydropyridazin-3(2H)-ones (2a-2l) with benzaldehyde. Molecular docking studies were carried out to determine the most active inhibitor of the Angiotensin Converting Enzyme (ACE). The compound (3a) was identified as the most active inhibitor of the ACE. The in vitro enzymatic ACE inhibitory activity of the compound (3a) using Dojindo ACE Kit-WST test kit revealed that the compound (3a) had IC_(50) value of 4.40 ìg/mL, wherein the standard drug Lisinopril had IC_(50) value of 0.99 ìg/mL. The comparison of the binding pattern of Lisinopril and the compound (3a) with the active sites of the ACE enzyme revealed that the incorporation of free amino groups and//or free carboxylic acid groups in the chemical structure of the compounds (3a-3l) may provide more active and potent ACE inhibitors.